[Form 4] Cytosorbents Corp. Insider Trading Activity

Rhea-AI Filing Summary

Phillip P. Chan, Chief Executive Officer and director of Cytosorbents Corp (CTSO), reported equity awards and holdings on 08/08/2025. The filing shows an acquisition of 105,600 restricted stock units (RSUs) with a reported price of $0 and a grant of 136,400 stock options with a $1 exercise price and an expiration date of 08/08/2035. Following the reported transactions, the filing reports 1,382,963 shares of common stock beneficially owned. Footnotes disclose multiple prior RSU grants (2015–2024), including 48,000 unvested RSUs from April 2, 2024, and state that 1,013,363 shares are owned outright by the reporting person. The RSUs and options vest in scheduled tranches and vesting generally requires continued service.

Positive

• 105,600 RSUs acquired reported on 08/08/2025 at a reported price of $0
• 136,400 stock options granted on 08/08/2025 with a $1 exercise price and expiration 08/08/2035
• Post-transaction beneficial ownership of 1,382,963 common shares reported

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: CEO Phillip Chan received 105,600 RSUs and 136,400 options; awards include explicit vesting schedules and a 10-year option term.

The filing documents standard executive equity awards on 08/08/2025: 105,600 RSUs reported at $0 and 136,400 options with a $1 exercise price expiring 08/08/2035. Footnotes detail prior RSU grants from 2015–2024 and outstanding common stock holdings. These disclosures are routine for executive compensation cycles and provide transparent vesting mechanics that condition future ownership on continued service.

Securities Analyst

TL;DR: The transaction increases reported insider holdings to 1,382,963 shares; disclosed vesting timelines and option terms are specified in the filing.

The Form 4 confirms post-transaction beneficial ownership of 1,382,963 common shares and direct beneficial ownership of 136,400 options. The filing specifies RSU and option vesting schedules and identifies previously granted RSUs and currently owned shares (including 1,013,363 shares owned outright). For investors, the filing provides clear metrics on insider holdings and the timing of potential future share issuance upon vesting or option exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Phillip P.

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		A		105,600(1)	A	$0	1,382,963(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1	08/08/2025		A		136,400		(5)	08/08/2035	Common Stock	136,400	$0	136,400	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

2. Includes: (i) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

3. (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof; and

4. (continued from footnote 3) (iv) 1,013,363 shares of Common Stock owned by the Reporting Person.

5. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Peter J. Mariani attorney-in-fact Phillip P. Chan	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity transactions did CTOs insider Phillip P. Chan report on 08/08/2025?

The filing reports an acquisition of 105,600 RSUs and a grant of 136,400 stock options on 08/08/2025.

How many shares does Phillip P. Chan beneficially own after the reported transactions (CTSO)?

The Form 4 reports 1,382,963 shares of common stock beneficially owned following the reported transactions.

What are the exercise price and expiration date for the stock options granted to Phillip P. Chan?

The stock options carry a $1 exercise price and an expiration date of 08/08/2035 as disclosed in the filing.

Do the RSUs and options have vesting conditions?

Yes. Footnotes state the RSUs and options vest in specified tranches and generally require the reporting person’s continued service for vesting to occur.

How many shares does the filing say Phillip P. Chan already owned outright?

Footnote 4 reports that the reporting person owns 1,013,363 shares of Common Stock outright.

Who signed the Form 4 filing for Phillip P. Chan?

The Form 4 was signed by attorney-in-fact Peter J. Mariani on 08/08/2025.